Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 9/20 | 0.55 |
| ▸ | NPC1 | O15118 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052435 | 0.88 | KMT2A (0.64) | MAPK1KMT2AHTTRAB9ANPC1 | |
| SCHEMBL18933496 | 0.85 | HTT (0.59) | MAPK1KMT2AHTTRAB9ANPC1 | |
| SCHEMBL14706023 | 0.85 | KMT2A (0.57) | MAPK1KMT2AHTTRAB9ANPC1 | |
| SCHEMBL16198428 | 0.84 | MAPK1 (0.68) | MAPK1KMT2ARAB9ANPC1MEN1 | |
| SCHEMBL15933265 | 0.84 | HTT (0.69) | MAPK1KMT2AHTTRAB9ANPC1 | |
| SCHEMBL13832785 | 0.83 | MAPK1 (0.71) | MAPK1KMT2ARAB9ANPC1MEN1 | |
| SCHEMBL2544046 | 0.83 | MAPK1 (1.00) | MAPK1KMT2ARAB9ANPC1MEN1 | |
| SCHEMBL1575018 | 0.82 | MAPK1 (0.61) | MAPK1KMT2AHTTRAB9ANPC1 | |
| SCHEMBL20209830 | 0.81 | HTT (0.56) | MAPK1KMT2AHTTRAB9ANPC1 | |
| SCHEMBL23889138 | 0.81 | MAPK1 (0.63) | MAPK1RAB9ANPC1PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-31 | — | — | US | disclosed |
| US-9902742-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2739628-B1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9611274-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9221818-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2013022818-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| US-6930116-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1251848-B1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040024030-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-05 | — | — | US | disclosed |
| US-20030170858-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-09-11 | — | — | US | disclosed |
| US-6608087-B1 | Treating bacterial infections in mammals | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-19 | — | — | US | disclosed |
| EP-1251848-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1251849-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001052845-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPOATED (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001052846-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | MAPK1 540/4885KMT2A 1182/4885HTT 2579/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | MAPK1 672/4885KMT2A 1029/4885HTT 2206/4885 |
| US-20160068544-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | MAPK1 540/4885KMT2A 1182/4885HTT 2579/4885 |
| US-20030170858-A1 | Gyrase inhibitors and uses thereof | HSPA4, HSPA1A, GRPR | MAPK1 561/4885KMT2A 4300/4885HTT 2873/4885 |
| US-20140221338-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | MAPK1 540/4885KMT2A 1182/4885HTT 2579/4885 |
| US-20170158712-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | MAPK1 540/4885KMT2A 1182/4885HTT 2579/4885 |
| US-20040024030-A1 | Gyrase inhibitors and uses thereof | TOP1, TOP2A, TOP2B | MAPK1 1141/4885KMT2A 3315/4885HTT 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.